Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oridonin
, a pharmacologically safe agent extracted from Isodon Serra, has been shown to possess potent anti-inflammatory properties. However, it is not clear whether
Oridonin
affects B-cell activating factor (BAFF) expression, thereby exerting beneficial effects in the treatment of BAFF-associated autoimmune diseases such as
systemic lupus erythematosus
(
SLE
). Thus, the current study aimed to find the function of
Oridonin
in regulation of BAFF and amelioration of
SLE
. In vitro, we explored the effect of
Oridonin
on BAFF expression and production in mouse macrophages. Moreover, using a spontaneous murine
SLE
model, we investigated the role of
Oridonin
delivery in the treatment of
lupus
-like disease in MRL(lpr/lpr) mice, by measuring the changes in
lupus
symptoms, renal damage, BAFF expression, and B cell subsets. Our results showed that
Oridonin
significantly inhibited BAFF expression in mouse macrophages by suppressing the transcriptional activation of its promoter. And in vivo administration of
Oridonin
efficiently ameliorated the serological and clinical manifestations of
SLE
in MRL(lpr/lpr) mice, as shown by increased survival benefit, reduced proteinuria levels, diminished production of specific auto-antibodies, and attenuated renal damage, in association with down-regulation of BAFF and a lower rate of B-cell maturation and differentiation. Thus, it suggests that
Oridonin
will serve as a novel natural therapeutic strategy for
SLE
by inhibition of BAFF.
...
PMID:Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). 2371 4
